BACKGROUND
Diabetic vitreous hemorrhage (DVH) is a common complication of diabetes. While the diagnostic methods nowadays only concentrate on the eye injury in DVH patients, whether DVH leads to abnormalities of other visual systems, including the eye, the visual cortex, and other brain regions, remains unknown.
AIM
To explore the potential changes of brain activity in DVH using regional homogeneity (ReHo) and their relationships with clinical features.
METHODS
Thirty-one DVH patients and 31 matched healthy controls (HCs) were recruited. All subjects were examined by resting-state functional magnetic resonance imaging. The neural homogeneity in the brain region was estimated by ReHo method. Pearson correlation analysis was used to evaluate the relationships between average ReHo values and clinical manifestations in DVH patients.
RESULTS
Compared with HCs, the ReHo values in the bilateral cerebellar posterior lobes, right superior (RS)/middle occipital gyrus (MOG), and bilateral superior frontal gyrus were significantly increased. In contrast, in the right insula, bilateral medial frontal gyri, and right middle frontal gyrus, the ReHo values were significantly decreased. Furthermore, we found that best-corrected visual acuity of the contralateral eye in patients with DVH presented a positive correlation with the mean ReHo value of the RS/MOG. We also found that depression score of the DVH group presented a negative correlation with the mean ReHo values of the right insula, bilateral medial frontal gyrus, and right middle frontal gyrus.
CONCLUSION
We found that DVH may cause dysfunction in multiple brain areas, which may benefit the exploration of pathologic mechanisms in DVH patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.